Immunological Strategies Against Pseudomonas Aeruginosa Infections

Pseudomonas aeruginosa is a versatile Gram-negative pathogen responsible for severe acute and chronic infections, particularly in immunocompromised individuals and patients with cystic fibrosis. Its intrinsic resistance mechanisms—encompassing efflux pumps, biofilm formation and adaptive persister cell development—challenge conventional antibiotic therapy. Immunological interventions seek to harness both innate and adaptive arms of the host defence, employing vaccines to generate protective antibodies and T-cell responses, monoclonal antibodies to confer passive immunity, and immunomodulatory agents to enhance phagocytic clearance. Emerging approaches include targeting virulence factors such as the type III secretion system, disrupting biofilms to improve immune access, and designing conjugate or mRNA vaccines that present conserved antigens in conjunction with optimised adjuvants. Together, these strategies aim to induce neutralising antibodies, promote opsonophagocytosis and stimulate T-helper cell subsets that support durable immunity. Successful deployment of these immunological measures would reduce reliance on antibiotics, curb the spread of multidrug-resistant strains and offer long-term protection for at-risk populations worldwide.

Research from Nature Portfolio

Recent studies have advanced protein-based and antibody-delivery platforms to prevent or treat P. aeruginosa infection. A trivalent subunit vaccine combining key outer membrane and secretion-system antigens demonstrated broad protection in murine pneumonia and burn models, eliciting high-titre antibodies that reduced bacterial load and inflammation. In parallel, DNA-encoded bispecific monoclonal antibodies delivered in vivo achieved sustained serum antibody levels, protected mice from lethal pneumonia and synergised with antibiotics to decrease organ colonisation. These innovations highlight the potential of antigen combinations and gene-based antibody delivery to provide rapid, targeted immunity against diverse clinical isolates.

Immunological Strategies Against Pseudomonas Aeruginosa Infections publication trend

The graph below shows the total number of articles in immunological strategies against pseudomonas aeruginosa infections across all publications each year (not limited to Nature Index journals).

Technical terms

Biofilm: A structured microbial community embedded in extracellular matrix that protects bacteria from antibiotics and immune effectors.

Opsonophagocytosis: The process by which antibodies and complement coat pathogens to enhance their uptake and destruction by phagocytes.

Glycoconjugate vaccine: A vaccine composed of carbohydrate antigens covalently linked to carrier proteins to improve immunogenicity.

mRNA vaccine: A formulation delivering messenger RNA encoding antigenic proteins, inducing transient in situ antigen expression and immune activation.

Monoclonal antibody: A laboratory-produced antibody targeting a single epitope, used for passive immunisation against specific antigens.

Type III secretion system (TTSS): A needle-like apparatus in Gram-negative bacteria that injects effector toxins directly into host cells, subverting immune responses.

References

1. Protective Efficacy of the Trivalent Pseudomonas aeruginosa Vaccine Candidate PcrV-OprI-Hcp1 in Murine Pneumonia and Burn Models. Scientific Reports (2017).
2. An engineered bispecific DNA-encoded IgG antibody protects against Pseudomonas aeruginosa in a pneumonia challenge model. Nature Communications (2017).
3. A Semisynthetic Oligomannuronic Acid-Based Glycoconjugate Vaccine against Pseudomonas aeruginosa. ACS Central Science (2024).
4. Development of innovative multi-epitope mRNA vaccine against Pseudomonas aeruginosa using in silico approaches. Briefings in Bioinformatics (2023).
5. Emerging therapies against infections with Pseudomonas aeruginosa. F1000Research (2019).